Anumigilimab

BIOLOGICAL2 trials

Sponsors

CSL Behring LLC, CSL Behring

Conditions

Sickle Cell Disease

Phase 2

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

RecruitingNCT07224360

CSL BehringSickle Cell Disease

Start: 2026-02-02End: 2028-06-29Target: 63Updated: 2026-08-05

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

Not yet recruitingCTIS2025-521154-42-00

CSL Behring LLCSickle Cell Disease

Target: 12Updated: 2026-04-29